Furthermore, the expression of HOXD1 was associated with decreased PFI patients in ACC, LIHC, STAD, and UCEC (p < 0.01) (Figure 3D); HOXD3 in ACC, KIRP, LGG, PRAD, and STAD (p < 0.01) (Figure 3E); HOXD4 in ACC, CESC, DLBC, KIRP, LGG, PRAD, and STAD (p < 0.01) (Figure 3F). Here, HOXD1 is linked to adrenal cortex carcinoma.